Navigation Links
Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
Date:8/5/2009

June 30, December 31, 2009 2008 (unaudited) Assets Current assets: Cash and cash equivalents $105,353,616 $47,627,246 Restricted cash 1,847,848 2,195,696 Prepaid expenses and other current assets 1,733,399 219,674 Total current assets 108,934,863 50,042,616 Property and equipment, net 5,447,615 4,477,020 Restricted cash 537,586 537,586 Other assets 33,554 90,792 Total assets $114,953,618 $55,148,014 Liabilities and Stockholders' Equity Current liabilities: Accounts payable 3,767,365 $4,877,854 Accrued liabilities 3,610,492 9,063,310 Current portion of long-term debt 6,377,275 7,694,173 Other current liabilities 22,048 22,048 Total current liabilities 13,777,180 21,657,385 Deferred rent 801,175 952,274 Long-term debt, less current portion and discount 3,179,199 6,098,113 Total stockholders' equity 97,196,064 26,440,242 Total liabilities and stockholders' equity $114,953,618 $55,148,014


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
3. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
5. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
6. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
7. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
11. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 Research and Markets  has ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... http://photos.prnewswire.com/prnh/20130307/600769 ... (either DNA or RNA) into cells. This technology helps ... cells and protein metabolism by affecting the nuclear genes. ...
(Date:7/11/2014)... MISSISSAUGA, ON , July 11, 2014 /CNW/ - ... Canada approved APTIOM TM (eslicarbazepine acetate) for use ... partial-onset seizures in patients with epilepsy who are not ... not indicated for use in patients under 18 years ... the most common neurological disorders and according to Epilepsy ...
(Date:7/10/2014)... Women in the West African ... additional family planning option. Sayana® Press has the ... levels of the health system and in communities ... used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with the BD ... first of four African countries expected to begin ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Understanding the ... channel-expressing cell lines, and the gap that currently exists ... that expand its industry-leading portfolio of validated ion channel ... ion channel-expressing cell lines, as ion channels control many ... control this activity creates the potential to treat a ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3
... ever admit to buying technology for technologys sake. And yet ... and deploy technology could be forgiven for believing thats what ... energy into specifying, acquiring and implementing the technology and almost ... that it is supposed to serve. From the way we ...
... giving birth to a new product, behave just like ... typical hysterical hoopla of the incubation wing is often ... becomes a subdued Dilbertish style revolution. Objects do fly, ... harmless, foamy projectiles. Everyone shares the excitement and all ...
... Financial Institutions MADISON, Wis. The Wisconsin ... low profile, although its actions have a significant ... department is going through a renaissance and increasing ... of Secretary Lorrie Keating Heinemann. , ,The DFI ...
Cached Biology Technology:Why are you buying technology? 2Why are you buying technology? 3Naming that thing... again? 2Naming that thing... again? 3Naming that thing... again? 4Wisconsin seeks to develop $10 million angel investment fund 2Wisconsin seeks to develop $10 million angel investment fund 3Wisconsin seeks to develop $10 million angel investment fund 4Wisconsin seeks to develop $10 million angel investment fund 5
(Date:7/11/2014)... cannabinoid receptor type 1 can inhibit voltage-gated ... reduce neurotransmitter release. However, some scholars demonstrated ... extracellular Ca2+ influx and increase neurotransmitter release. ... Hospital Affiliated to Tongji Medical College, Huazhong ... whole cell voltage-clamp and calcium imaging in ...
(Date:7/10/2014)... Albuquerque, and other major cities in New Mexico, nearly ... municipal wastewater rather than precious potable water supplies. Across ... of all golf courses receive treated effluent. Reusing the ... Additionally, golf courses and homeowners alike fertilize their lawns ... is nitrate. A New Mexico State University turfgrass expert ...
(Date:7/10/2014)... 1, 2014 Smart technology emphasis grows ... and improved security: NXT-ID, Inc. (OTCBB: NXTD), eBay Inc. (NASDAQ: ... ), Apple Inc. (NASDAQ: AAPL ), Visa Inc. ... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused ... the second series of 30 second spots on CNBC for ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5
... scientists at the American Museum of Natural History suggests that ... food sources. As Arctic sea ice melts earlier and freezes ... time to hunt their historically preferred preyringed seal pupsand must ... at least some polar bears in the western Hudson Bay ...
... children exposed to high levels of air pollutants were nearly ... children and lower levels of pollution exposure, report researchers at ... obesity and asthma have both increased dramatically in the past ... has increased from 7% in 1980 to 20% in 2008. ...
... with unique strands of DNA like barcodes ... a billion prototype drug molecules for anti-cancer activity, ... Institute of Cancer Research, London, Cancer Research Technology ... Researchers will use Nuevolution,s novel screening technology, ...
Cached Biology News:Polar bear diet changes as sea ice melts 2Obese children more susceptible to asthma from air pollution 2International deal to screen potential cancer drugs using DNA 'barcodes' 2International deal to screen potential cancer drugs using DNA 'barcodes' 3
ssDNA from PCR DNA in less than 1 hour. No gels, columns, or slurries. Sequence from high quality ssDNA: clearer reads, longer runs....
Applications: Immunohistochemistry, ISH, FISH, CISH....
... fit into the Universal Test ... to greatly increase your microplate ... plates at an angle, and ... shaker at once for quick ...
Mixing speed from 750-3200RPM, small vortexing orbit of1.0mm...
Biology Products: